BNB Plus Corp. (BNBX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments.
Price
| Price | $0.16 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.13 |
| EV / EBITDA | -0.04 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -657.80% |
| Return on Invested Capital | -708.18% |
| Return on Assets | -341.65% |
| Gross Margin | 43.49% |
| Operating Margin | -1209.55% |
| Net Margin | -1646.94% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -130.65 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BNBX | BNB Plus Corp. | 0.13 | -6.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Explore sector: Healthcare · Biotechnology
More sections of BNBX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks